A preliminary investigation of the effects of cognitive behavioral therapy for panic disorder on gastrointestinal distress in patients with comorbid panic disorder and irritable bowel syndrome
Mental Health Service, Ralph H. Johnson VAMC, Charleston, South Carolina 29401, USA. Depression and Anxiety
(Impact Factor: 4.41).
11/2011; 28(11):1027-33. DOI: 10.1002/da.20863
High comorbidity between panic disorder with/without agoraphobia (PD/A) and irritable bowel syndrome (IBS) has been identified in the literature. These findings have resulted in the recent development of neurobiological models to explain their overlapping symptoms and related origins. This study was a preliminary investigation of the influence of cognitive behavioral therapy (CBT) for PD/A on PD/A patients with and without comorbid IBS.
All patients completed a thorough intake assessment, brief waitlist period, and a 12-week CBT group for PD/A.
The results demonstrated significant reductions in the symptoms of anxiety, depression, and overall impairment in both patient groups (ts>2.3; Ps<.05). In addition, PD/A patients with comorbid IBS also experienced reductions in the disability and distress associated with their gastrointestinal symptoms of IBS (ts>1.9; Ps<.07).
Although additional research still is needed, these preliminary findings suggest that CBT for PD/A can be used to simultaneously treat comorbid symptoms of PD/A and IBS. Implications for the neurobiological models for these comorbid conditions were discussed.
Available from: D. Scott Sibley
- "In addition, Moylan, Staples, Ward, Rogerson, Stein, and Berk (2011) reported no statistically significant differences between the use of alprazolam or other benzodiazepines in the treatment of panic disorder symptoms. A significant amount of empirical evidence has supported the use of cognitive behavioral therapy (CBT) to treat depressive and anxious symptoms associated with panic disorder (El Alaoui et al., 2013; Clum & Surls, 1993; Gros et al., 2011a; Mitte, 2005; Schmidt & Woolway-Bickel, 2000). Cognitive behavioral therapy for panic disorder includes training clients to become aware of bodily sensations associated with anxious arousal (Arch & Craske, 2011), increase self-efficacy, and reduce catastrophic thinking. "
Journal of Family Psychotherapy 12/2015; DOI:10.1080/08975353.2015.1097285
Available from: Mihaela Fadgyas Stanculete
[Show abstract] [Hide abstract]
ABSTRACT: Irritable bowel syndrome (IBS) is a functional syndrome characterized by chronic abdominal pain accompanied by altered bowel habits. Although generally considered a functional disorder, there is now substantial evidence that IBS is associated with a poor quality of life and significant negative impact on work and social domains. Neuroimaging studies documented changes in the prefrontal cortex, ventro-lateral and posterior parietal cortex and thalami, and implicate alteration of brain circuits involved in attention, emotion and pain modulation. Emerging data reveals the interaction between psychiatric disorders including generalized anxiety disorder, panic disorder, major depressive disorder, bipolar disorder, and schizophrenia and IBS, which suggests that this association should not be ignored when developing strategies for screening and treatment. Psychological, social and genetic factors appear to be important in the development of IBS symptomatology through several mechanisms: alteration of HPA axis modulation, enhanced perception of visceral stimuli or psychological vulnerability. Elucidating the molecular mechanisms of IBS with or without psychiatric comorbidities is crucial for elucidating the pathophysiology and for the identification of new therapeutical targets in IBS.
Keywords: Irritable bowel syndrome; Psychiatric disorders; Comorbidities; Brain-gut axis; Psychosocial factors
06/2014; 2(4). DOI:10.1186/2049-9256-2-4
Available from: wjgnet.com
[Show abstract] [Hide abstract]
To investigate the efficacy of tandospirone in patients with irritable bowel syndrome-diarrhea (IBS-D) and anxiety in a prospective, randomized, controlled study.
Two hundred patients with IBS-D and moderate anxiety were randomized to receive pinaverium and tandospirone (arm A) or pinaverium and placebo (arm B). Tandospirone or placebo was given thrice daily at a fixed dose of 10 mg and pinaverium was given thrice daily at a fixed dose of 50 mg. The duration of treatment was 8 wk. Patients were assessed for abdominal pain and diarrhea. Anxiety was evaluated using the Hamilton Rating Scale for Anxiety (HAM-A). The primary study endpoints were response rates for abdominal pain and diarrhea. The secondary study endpoints were response rates for anxiety. Adverse events were also evaluated.
One hundred and seventy of 200 patients (82 patients in arm A and 88 patients in arm B) completed the study. Demographic and baseline characteristics of the 200 participants were comparable in the two arms. At week 8, the overall response rate for abdominal pain and diarrhea was 52.0% for arm A and 37.0% for arm B (P < 0.05). The HAM-A score showed that the response rate was 61.0% for arm A and 21.0% for arm B (P < 0.01). The treatments were well tolerated and no significant adverse events were reported.
Tandospirone is effective and can be combined with pinaverium in IBS-D patients with anxiety.
World Journal of Gastroenterology 08/2014; 20(32):11422-8. DOI:10.3748/wjg.v20.i32.11422 · 2.37 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.